TY - JOUR
T1 - Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis
AU - Gerber, David E.
AU - Beg, M. Shaalan
AU - Fattah, Farjana
AU - Frankel, Arthur E.
AU - Fatunde, Oluwatomilade
AU - Arriaga, Yull
AU - Dowell, Jonathan E.
AU - Bisen, Ajit
AU - Leff, Richard D.
AU - Meek, Claudia C.
AU - Putnam, William C.
AU - Kallem, Raja Reddy
AU - Subramaniyan, Indhumathy
AU - Dong, Ying
AU - Bolluyt, Joyce
AU - Sarode, Venetia
AU - Luo, Xin
AU - Xie, Yang
AU - Schwartz, Brian
AU - Boothman, David A.
N1 - Funding Information:
Competing interests: D.E.G. has received research funding from ArQule, Inc. B.S. is an employee of ArQule, Inc. The other authors declare no competing interests.
Funding Information:
The authors thank Ms. Dru Gray for assistance with manuscript preparation. This work was supported in part by a National Cancer Institute at the National Institutes of Health, Midcareer Investigator Award in Patient-Oriented Research (K24CA201543–01; to D.E.G.), a National Cancer Institute Cancer Clinical Investigator Team Leadership Award (1P30 CA142543–01 supplement; to D.E.G.), the Harold C. Simmons Comprehensive Cancer Center at the University of Texas Southwestern Medical Center (1P30 CA142543–03), and ArQule, Inc. Research reported in this publication was supported in part by the Harold C. Simmons Comprehensive Cancer Center’s Biomarker Research Core and Biostatistics and Bioinformatics Shared Resource, which are supported by NCI Cancer Center Support Grant 1P30 CA142543–03. Additionally, research reported in this publication was supported in part by Cancer Prevention Research Institute of Texas Core Facilities Support Award (RP170003; to W.C.P.).
Publisher Copyright:
© 2018, Cancer Research UK.
PY - 2018/10/16
Y1 - 2018/10/16
N2 - Background: NAD(P)H:quinone oxidoreductase 1 (NQO1) is a two-electron oxidoreductase expressed in multiple tumour types. ARQ 761 is a β-lapachone (β-lap) analogue that exploits the unique elevation of NQO1 found in solid tumours to cause tumour-specific cell death. Methods: We performed a 3+3 dose escalation study of 3 schedules (weekly, every other week, 2/3 weeks) of ARQ 761 in patients with refractory advanced solid tumours. Tumour tissue was analysed for NQO1 expression. After 20 patients were analysed, enrolment was restricted to patients with NQO1-high tumours (H-score ≥ 200). Results: A total of 42 patients were treated. Median number of prior lines of therapy was 4. Maximum tolerated dose was 390 mg/m2 as a 2-h infusion every other week. Dose-limiting toxicity was anaemia. The most common treatment-related adverse events were anaemia (79%), fatigue (45%), hypoxia (33%), nausea (17%), and vomiting (17%). Transient grade 3 hypoxia, reflecting possible methemoglobinaemia, occurred in 26% of patients. Among 32 evaluable patients, best response was stable disease (n = 12); 6 patients had tumour shrinkage. There was a trend towards improved efficacy in NQO1-high tumours (P = 0.06). Conclusions: ARQ 761 has modest single-agent activity, which appears associated with tumour NQO1 expression. Principal toxicities include anaemia and possible methemoglobinaemia.
AB - Background: NAD(P)H:quinone oxidoreductase 1 (NQO1) is a two-electron oxidoreductase expressed in multiple tumour types. ARQ 761 is a β-lapachone (β-lap) analogue that exploits the unique elevation of NQO1 found in solid tumours to cause tumour-specific cell death. Methods: We performed a 3+3 dose escalation study of 3 schedules (weekly, every other week, 2/3 weeks) of ARQ 761 in patients with refractory advanced solid tumours. Tumour tissue was analysed for NQO1 expression. After 20 patients were analysed, enrolment was restricted to patients with NQO1-high tumours (H-score ≥ 200). Results: A total of 42 patients were treated. Median number of prior lines of therapy was 4. Maximum tolerated dose was 390 mg/m2 as a 2-h infusion every other week. Dose-limiting toxicity was anaemia. The most common treatment-related adverse events were anaemia (79%), fatigue (45%), hypoxia (33%), nausea (17%), and vomiting (17%). Transient grade 3 hypoxia, reflecting possible methemoglobinaemia, occurred in 26% of patients. Among 32 evaluable patients, best response was stable disease (n = 12); 6 patients had tumour shrinkage. There was a trend towards improved efficacy in NQO1-high tumours (P = 0.06). Conclusions: ARQ 761 has modest single-agent activity, which appears associated with tumour NQO1 expression. Principal toxicities include anaemia and possible methemoglobinaemia.
UR - http://www.scopus.com/inward/record.url?scp=85054923462&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054923462&partnerID=8YFLogxK
U2 - 10.1038/s41416-018-0278-4
DO - 10.1038/s41416-018-0278-4
M3 - Article
C2 - 30318513
AN - SCOPUS:85054923462
SN - 0007-0920
VL - 119
SP - 928
EP - 936
JO - British journal of cancer
JF - British journal of cancer
IS - 8
ER -